TSX: MFI
www.mapleleaffoods.com
Meat Protein delivers top-line growth of 5.9% and
Adjusted EBITDA Margin of 6.6% in the quarter
Plant Protein progressing toward Adjusted EBITDA
target of neutral or better in the latter half of 2023
MISSISSAUGA, ON, March 9,
2023 /PRNewswire/ - Maple Leaf Foods Inc. ("Maple
Leaf Foods" or "the Company") (TSX: MFI) today reported its
financial results for the fourth quarter and full year ended
December 31, 2022.
"2022 was clearly a year of unprecedented challenges for us on
many fronts, including hyper-inflation, dislocation in the pork
markets, supply chain dysfunction, job vacancies and a
cyber-attack," said Michael H.
McCain, Chief Executive Officer of Maple Leaf Foods.
"Despite this tumultuous environment, we have maintained a steady
hand on executing our plans including aggressively building our
sustainability platform, starting up over a $1 billion of new assets and converting our
plant-based business model to profitable growth. Of course, our
fourth quarter results are not where we like them to be, given
these unprecedented market conditions and the impacts of the
cyber-attack, but the underlying health of the business in normal
markets is solid and in-line with where we expected to be at this
point."
"We continue to see an inflection point in our business,"
continued Mr. McCain, "The start-up of the London Poultry plant is
going exceptionally well and on schedule, we are on-track to get to
Adjusted EBITDA neutral or better in our plant-based business this
year, our supply chains are normalizing now, the imbalance in our
pricing for inflation is now coming into line and important Asian
regions have opened up again for us. These unprecedented markets
will normalize; they always do."
Fourth Quarter 2022 Highlights
- Total Company sales growth of 5.8% to $1,185.5 million, with an Adjusted Earnings
Before Interest, Taxes, Depreciation and Amortization
("EBITDA")(i) margin of 4.7%.
- Meat Protein Group sales grew to $1,149.6 million, an increase of 5.9% year over
year. Adjusted EBITDA was $76.1
million, Adjusted EBITDA margin was 6.6%.
- Plant Protein Group sales were $40.0
million. Plant Protein Group Adjusted EBITDA improved by
53.5% year over year to a loss of $20.4
million, en route to an Adjusted EBITDA target of neutral or
better in the latter half of 2023.
- Capital expenditures were $56.8
million.
- The London Poultry facility started commercial production in
the quarter, on schedule.
- The Company was affected by a cybersecurity incident, which had
an estimated adverse economic impact of at least $23 million.
2022 Highlights
- Total Company sales grew by 4.8% to $4,739.1 million, with an Adjusted EBITDA margin
of 5.8%.
- Meat Protein Group sales grew to $4,593.6 million, an increase of 5.2%. Adjusted
EBITDA was $378.7 million and
Adjusted EBITDA Margin was 8.2%.
- Plant Protein Group Sales were $169.3
million. Plant Protein Group Adjusted EBITDA improved by
17.1% to a loss of $105.4
million.
- Capital expenditures of $312.1
million included Construction Capital(i)
of $163.7 million, the majority of
which was related to long-term investments in the London Poultry
facility.
- The balance sheet remains strong, with Net
Debt(i) of $1,619.3
million and undrawn committed credit of $291.5 million.
Outlook
- Meat Protein: Expect mid-to-high single digit sales
growth in 2023, and Adjusted EBITDA Margin expansion to achieve a
target range of 14% - 16% when conditions normalize.
- Plant Protein: Targeting to deliver neutral or better
Adjusted EBITDA in the latter half of 2023.
- Capital expenditure: for 2023 is expected to be less
than $250 million with up to
$120 million attributable to
maintenance projects and the balance attributable to growth
capital.
(i) Refer to the section
titled Non-IFRS Financial Measures in this news
release.
|
Financial Highlights
|
|
|
|
|
|
|
As at or for
the
|
Measure(i)
(Unaudited)
|
Three months ended
December 31,
|
Twelve months ended
December 31,
|
|
2022
|
|
2021
|
|
Change
|
|
2022
|
|
2021
|
|
Change
|
Sales
|
|
$
1,185.5
|
|
$
1,120.5
|
|
5.8 %
|
|
$
4,739.1
|
|
$
4,521.1
|
|
4.8 %
|
Net (Loss)
Earnings
|
|
$
(41.5)
|
|
$
1.9
|
|
nm(iii)
|
|
$
(311.9)
|
|
$
102.8
|
|
nm(iii)
|
Basic (Loss) Earnings
per Share
|
|
$
(0.34)
|
|
$
0.02
|
|
nm(iii)
|
|
$
(2.52)
|
|
$
0.83
|
|
nm(iii)
|
Adjusted Operating
Earnings(ii)
|
|
$
1.8
|
|
$
30.0
|
|
(93.8) %
|
|
$
65.7
|
|
$
210.3
|
|
(68.7) %
|
Adjusted (Loss)
Earnings per Share(ii)
|
|
$
(0.28)
|
|
$
0.09
|
|
(411.1) %
|
|
$
(0.26)
|
|
$
1.03
|
|
(125.2) %
|
Adjusted EBITDA - Meat
Protein Group(ii)
|
|
$
76.1
|
|
$
120.7
|
|
(37.0) %
|
|
$
378.7
|
|
$
527.1
|
|
(28.2) %
|
Adjusted EBITDA - Plant
Protein Group(ii)
|
|
$
(20.4)
|
|
$
(43.9)
|
|
53.5 %
|
|
$
(105.4)
|
|
$
(127.2)
|
|
17.1 %
|
Sales - Plant Protein
Group
|
|
$
40.0
|
|
$
45.5
|
|
(12.1) %
|
|
$
169.3
|
|
$
184.1
|
|
(8.0) %
|
Free Cash
Flow(ii)(iv)
|
|
$
20.7
|
|
$
144.2
|
|
(85.6) %
|
|
$
(20.9)
|
|
$
213.0
|
|
(109.8) %
|
Construction
Capital(ii)
|
|
|
|
|
|
|
|
$
9.6
|
|
$
743.3
|
|
(98.7) %
|
Net
Debt(ii)
|
|
|
|
|
|
|
|
$
(1,619.3)
|
|
$
(1,090.2)
|
|
(48.5) %
|
(i) All financial measures
in millions of dollars except Basic and Adjusted Earnings per
Share.
|
(ii) Refer to the section
titled Non-IFRS Financial Measures in this news
release.
|
(iii) Not
meaningful.
|
(iv) Certain comparative
figures have been restated to conform with current year
presentation.
|
Fourth Quarter 2022
Sales for the fourth quarter increased 5.8% to $1,185.5 million compared to $1,120.5 million last year. The increase is
attributable to pricing actions taken earlier in the year, growth
in sustainable meats, and foreign exchange which were partially
offset by lower volumes.
Net loss for the fourth quarter of 2022 was $41.5 million ($0.34 loss per basic share) compared to net
earnings of $1.9 million
($0.02 per basic share) last year.
Net loss for the quarter was negatively impacted by weaker markets
in pork and an estimated economic impact of at least $23 million from the cybersecurity incident,
which more than offset strong performance in packaged meats, growth
in sustainable meats, and a reduction in Plant Protein losses
resulting from the shift to a strategy of profitable growth. Net
loss for the fourth quarter of 2022 also included start-up expenses
of $25.8 million (2021: $7.7 million) associated with Construction
Capital projects.
Adjusted Operating Earnings for the fourth quarter of 2022 were
$1.8 million compared to $30.0 million last year, consistent with the
factors noted above.
Adjusted EBITDA Margin for the fourth quarter decreased to 4.7%
from 6.8% last year, consistent with the factors noted above.
Basic Earnings per Share was a loss of $0.34 for the fourth quarter of 2022 compared to
$0.02 last year, consistent with the
factors described above.
Adjusted Earnings per Share in the fourth quarter of 2022 was a
loss of $0.28 compared to
$0.09 last year.
Full Year 2022
Sales for 2022 were $4,739.1
million compared to $4,521.1
million last year, an increase of 4.8%, driven by pricing
action to mitigate inflation, growth in sustainable meats, and
foreign exchange partly offset by lower volumes.
Net loss for 2022 was $311.9
million ($2.52 loss per basic
share) compared to earnings of $102.8
million ($0.83 per basic
share) last year. Strong performance in the packaged meats
portfolio was more than offset by weaker results in pork processing
and hog production operations, inflation, and labour challenges, as
well as an estimated economic impact of the cybersecurity incident
of at least $23 million. Interest
expense increased by $33.2 million,
reflecting the net debt levels associated with Construction Capital
projects and increases in variable borrowing rates. Net Loss for
the year also included a $190.9
million one-time impairment charge related to the Plant
Protein Group, start-up expenses of $59.3
million (2021: $13.4 million)
associated with Construction Capital projects, as well as net
losses from non-cash fair value changes in biological assets and
derivative contracts of $14.0 million
(2021: $4.9 million), all of which
are excluded in the calculation of Adjusted Operating Earnings.
Adjusted Operating Earnings for 2022 were $65.7 million compared to $210.3 million last year, and Adjusted Earnings
per Share for 2022 was a loss of $0.26 compared to
$1.03 last year.
For further discussion on key metrics and a discussion of
results by operating segment, refer to the section titled Operating
Review.
Note: Several items are excluded from the discussions
of underlying earnings performance as they are not representative
of ongoing operational activities. Refer to the section entitled
Non-IFRS Financial Measures at the end of this news release for a
description and reconciliation of all non-IFRS financial
measures.
|
Cybersecurity Incident
On November 6, 2022 the Company
confirmed that it experienced a system outage stemming from a
cybersecurity incident. Upon learning of the incident, Maple Leaf
Foods took immediate action and engaged cybersecurity and recovery
experts. The Company executed is business continuity plans as it
restored the impacted systems, and worked with customers and
suppliers to minimize service disruptions. While the Company was
able to maintain operations throughout the event, normal business
activities were interrupted. The Company estimates that the direct
and indirect economic impact of this event in the fourth quarter
was at least $23 million.
Response to COVID-19
As an essential service, Maple Leaf Foods is focused on
protecting the health and well-being of its people, maintaining
business continuity and broadening its social outreach. To manage
through this unprecedented environment, the Company has taken a
number of measures in its business and operating practices that
include heightened safety policies and procedures, adopting a
vaccination mandate for all employees and contractors, and close
communication and collaboration with public health authorities,
including hosting on-site vaccination clinics in 2021. The measures
enacted to protect the health and safety of employees increased the
Company's cost structure during the pandemic due to higher labour,
personal protective equipment, sanitation and other expenses.
Overall, the Company believes its proactive and comprehensive
efforts have, and should continue to mitigate adverse operational
impacts. As the COVID-19 situation evolves, Maple Leaf Foods will
continue to adapt and adopt best practices that prioritize the
health and safety of its employees and the stability of the food
supply. As part of Maple Leaf Foods' broader social responsibility
during the pandemic, the Company has provided extensive support to
front-line staff, emergency food relief efforts and health care
providers.
Operating Review
During the year ended December 31, 2022, the Company
had two reportable segments. These segments offer different
products, with separate organizational structures, brands, and
financial and marketing strategies. The Company's chief operating
decision makers regularly review internal reports for these
businesses. Performance of the Meat Protein Group is based on
profitable revenue growth, Adjusted Operating Earnings and Adjusted
EBITDA, while the performance of the Plant Protein Group in the
short term is focused on obtaining Adjusted EBITDA neutral or
better results.
Fourth Quarter 2022
The following table summarizes the Company's sales, gross
profit, SG&A expenses, Adjusted Operating Earnings, Adjusted
EBITDA, and Adjusted EBITDA Margin by operating segment for
the fourth quarters ended December 31, 2022 and
December 31, 2021:
|
Three months ended
December 31, 2022
|
Three months ended
December 31, 2021
|
($
millions)(i)
(Unaudited)
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Sales
|
$
1,149.6
|
40.0
|
(4.1)
|
$
1,185.5
|
$
1,085.2
|
45.5
|
(10.2)
|
$
1,120.5
|
Gross profit
(loss)
|
$
82.2
|
(10.3)
|
28.7
|
$
100.6
|
$ 152.2
|
(10.0)
|
0.1
|
$ 142.3
|
Selling, general and
administrative
expenses
|
$
80.0
|
15.8
|
—
|
$
95.9
|
$
80.2
|
39.8
|
—
|
$ 120.0
|
Adjusted Operating
(Loss) Earnings(iii)
|
$
28.0
|
(26.2)
|
—
|
$
1.8
|
$
77.8
|
(47.8)
|
—
|
$
30.0
|
Adjusted
EBITDA(iii)
|
$
76.1
|
(20.4)
|
(0.5)
|
$
55.3
|
$ 120.7
|
(43.9)
|
(0.4)
|
$
76.3
|
Adjusted EBITDA
Margin(iii)
|
6.6 %
|
(51.0) %
|
n/a
|
4.7 %
|
11.1 %
|
(96.6) %
|
n/a
|
6.8 %
|
(i)
|
Totals may not add due to
rounding.
|
(ii)
|
Non-allocated includes eliminations of inter-segment
sales and associated cost of goods sold, changes in the fair value
of biological assets and derivatives, and non-allocated costs which
are comprised of expenses not separately identifiable to reportable
segments or are not part of the measures used by the Company when
assessing a segment's operating
results.
|
(iii)
|
Refer to the section
titled Non-IFRS Financial Measures in this news
release.
|
Meat Protein Group
The Meat Protein Group is comprised of prepared meats,
ready-to-cook and ready-to-serve meals, snack kits, value-added
fresh pork and poultry products that are sold to retail,
foodservice and industrial channels, and agricultural operations in
pork and poultry. The Meat Protein Group includes leading brands
such as Maple Leaf®, Maple Leaf Prime®, Maple Leaf Natural
Selections®, Schneiders®, Schneiders® Country Naturals®, Mina®,
Greenfield Natural Meat Co.®, and other leading regional
brands.
Sales for the fourth quarter increased 5.9% to $1,149.6 million compared to $1,085.2 million last year. Sales growth was
driven by pricing action implemented in prior quarters to mitigate
inflation and structural cost increases, growth in sustainable
meats and favorable foreign exchange, partially offset by lower
volumes including the impact of the cybersecurity incident.
Gross profit for the fourth quarter of 2022 was
$82.2 million (gross margin of 7.2%)
compared to $152.2 million (gross
margin of 14.0%) last year. The decrease was driven by market
headwinds, impact of the cybersecurity incident, inflation and
labour challenges partially offset by pricing actions taken earlier
in the year. Gross profit for the fourth quarter of 2022 also
included start-up expenses of $25.8
million (2021: $5.8 million)
associated with Construction Capital projects which are excluded in
the calculation of Adjusted Operating Earnings.
SG&A expenses for the fourth quarter of 2022 were
$80.0 million consistent with
$80.2 million last year including
incremental cybersecurity incident related costs offset by lower
variable compensation.
Adjusted Operating Earnings for the fourth quarter of
2022 were $28.0 million compared
to $77.8 million last year, driven by
the factors noted above.
Adjusted EBITDA Margin for the fourth quarter was
6.6% compared to 11.1% last year, consistent with the factors
noted above.
Plant Protein Group
The Plant Protein Group is comprised of refrigerated plant
protein products, premium grain-based protein, and vegan cheese
products sold to retail, foodservice and industrial channels. The
Plant Protein Group includes the leading brands Lightlife® and
Field Roast™.
Sales for the fourth quarter were $40.0 million compared to $45.5 million last year, representing a decline
of 11.9%, or 18.2% excluding the impact of foreign exchange. Sales
decline was driven by lower retail and foodservice product volumes,
partially offset by price increases.
Gross profit for the fourth quarter of 2022 was a loss of
$10.3 million (gross margin loss of
25.8%) compared to a loss of $10.0
million (gross margin loss of 21.9%) last year. The decrease
in gross profit was driven by inflation in materials, freight, and
labour as well as strategic investments in capacity to build for
anticipated demand, which has resulted in increased overhead costs.
This was partially offset by pricing action. Gross profit for the
fourth quarter of 2021 included start-up expenses of $2.0 million associated with Construction Capital
projects which are excluded in the calculation of Adjusted
Operating Earnings.
SG&A expenses for the fourth quarter of 2022 were
$15.8 million (39.5% of sales),
compared to $39.8 million (87.6% of
sales) last year. The decrease in SG&A expenses was primarily
attributable to lower advertising expenses and people costs as a
result of the restructuring plan implemented towards the end of the
second quarter.
Adjusted Operating Earnings for the fourth quarter of
2022 were a loss of $26.2
million compared to a loss of $47.8
million last year. The improvement in Adjusted Operating
Earnings is consistent with the factors noted above.
Adjusted EBITDA for the fourth quarter of 2022 was a loss of
$20.4 million compared to a loss of
$43.9 million last year, consistent
with the factors noted above.
Full Year 2022
The following table summarizes the Company's sales, gross
profit, SG&A expenses, Adjusted Operating Earnings, Adjusted
EBITDA, and Adjusted EBITDA Margin by operating segment for
the years ended December 31, 2022 and December 31,
2021.
|
2022
|
2021
|
($
millions)(i)
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Meat Protein
Group
|
Plant Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Sales
|
$
4,593.6
|
169.3
|
(23.9)
|
$
4,739.1
|
$
4,366.7
|
184.1
|
(29.8)
|
$
4,521.1
|
Gross profit
(loss)
|
$
474.7
|
(36.5)
|
(14.0)
|
$
424.1
|
$ 676.8
|
(12.8)
|
(4.9)
|
$ 659.1
|
Selling, general and
administrative
expenses
|
$
338.9
|
92.8
|
—
|
$
431.7
|
$ 334.3
|
132.8
|
—
|
$ 467.1
|
Adjusted Operating
(Loss) Earnings(iii)
|
$
190.3
|
(124.5)
|
—
|
$
65.7
|
$ 352.4
|
(142.1)
|
—
|
$ 210.3
|
Adjusted
EBITDA(iii)
|
$
378.7
|
(105.4)
|
(0.5)
|
$
272.9
|
$ 527.1
|
(127.2)
|
(0.4)
|
$ 399.5
|
Adjusted EBITDA
Margin(iii)
|
8.2 %
|
(62.2) %
|
n/a
|
5.8 %
|
12.1 %
|
(69.1) %
|
n/a
|
8.8 %
|
(i)
|
Totals may not add due to
rounding.
|
(ii)
|
Non-allocated includes eliminations of inter-segment
sales and associated cost of goods sold, changes in the fair value
of biological assets and derivatives, and non-allocated costs which
are comprised of expenses not separately identifiable to reportable
segments or are not part of the measures used by the Company when
assessing a segment's operating results.
|
(iii)
|
Refer to the section
titled Non-IFRS Financial Measures in this news
release.
|
Meat Protein Group
Sales for 2022 increased 5.2% to $4,593.6 million compared to $4,366.7 million last year. Sales growth was
driven by pricing actions to mitigate inflationary cost increases,
favourable mix-shift towards sustainable meats, growth in
the United States and favourable
foreign exchange. These positive factors were partially offset by
lower sales volume.
Gross profit for 2022 was $474.7
million (gross margin of 10.3%) compared to $676.8 million (gross margin of 15.5%) last year.
Gross profit was negatively impacted by labour and supply chain
disruptions, inflationary cost increases, volume declines, pork
market headwinds, including challenges in the Japanese market, and
the cybersecurity incident. This was partially offset by pricing
actions. Gross profit also included start-up expenses of
$54.5 million (2021: $9.9 million) associated with Construction
Capital projects, which are excluded in the calculation of Adjusted
Operating Earnings.
SG&A expenses for 2022 were $338.9 million which is consistent with last
year's expenses of $334.3
million.
Adjusted Operating Earnings for 2022 were $190.3 million compared to $352.4 million last year, driven by factors
noted above.
Adjusted EBITDA for 2022 were $378.7
million compared to $527.1
million last year, driven by factors consistent with those
noted above. Adjusted EBITDA Margin for 2022 was 8.2% compared to
12.1% last year, also driven by factors consistent with those noted
above.
Plant Protein Group
Sales for 2022 were $169.3
million compared to $184.1
million last year, representing a decrease of 8.0%, or 11.4%
after excluding the impacts of foreign exchange. The sales decline
was driven by lower retail product volumes, which more than offset
pricing action implemented throughout 2022 to mitigate inflation
and structural cost increases.
Gross loss for 2022 was a loss of $36.5 million (gross margin loss of
21.6%) compared to a gross loss of $12.8 million (gross margin loss of 7.0%) last
year. The decrease in gross profit was attributed to lower sales
volumes and strategic investments in capacity to build for
anticipated demand, which has resulted in increased overhead and
transitory costs, as well as inflationary pressures on distribution
and input costs. Gross loss for 2022 also included start-up
expenses of $4.8 million (2021:
$3.5 million) associated with
Construction Capital projects which are excluded in the calculation
of Adjusted Operating Earnings.
SG&A expenses for 2022 were $92.8 million (54.8% of sales) compared to
$132.8 million (72.1% of sales) last
year. The decrease in SG&A expenses was primarily attributable
to lower advertising expenses and people costs as a result of the
restructuring activities implemented towards the end of the second
quarter of 2022 in response to the change in strategic plan, as
further described in the Outlook section of this document,
partially offset by higher consulting costs.
Adjusted Operating Earnings for 2022 were a loss of
$124.5 million compared to a loss of
$142.1 million last year. This
improvement is consistent with the factors noted above.
Adjusted EBITDA for 2022 was a loss of $105.4 million compared to a loss of $127.2 million last year. This improvement
is consistent with the factors noted above.
Other Matters
On March 8, 2023, the Board of
Directors approved a quarterly dividend of $0.21 per share (an increase of $0.01 per share from the 2022 fourth quarter
dividends), $0.84 per share on an
annual basis, payable March 31, 2023
to shareholders of record at the close of business March 24, 2023. Unless indicated otherwise by the
Company at or before the time the dividend is paid, the dividend
will be considered an eligible dividend for the purposes of the
"Enhanced Dividend Tax Credit System".
Conference Call
A conference call will be held at 8:00 a.m. ET on
March 9, 2023, to review Maple Leaf Foods' fourth quarter
financial results. To participate in the call, please dial
416-764-8650 or 1-888-664-6383. For those unable to participate,
playback will be made available an hour after the event at
416-764-8677 or 1-888-390-0541 (Passcode: 672805#).
A webcast of the fourth quarter conference call will also be
available at: https://www.mapleleaffoods.com.
The Company's full consolidated financial statements
("Consolidated Financial Statements") and related Management's
Discussion and Analysis are available on the Company's website.
An investor presentation related to the Company's fourth quarter
financial results is available at www.mapleleaffoods.com and can be
found under Presentations and Webcasts on the Investors page.
Outlook
Maple Leaf Foods is a leading consumer protein company,
supported by a portfolio of market leading brands, a solid balance
sheet and capital structure that provide financial flexibility.
Over the last several years, the Company has developed a foundation
to pursue compelling growth vectors across its business and to
create value for all stakeholders.
Meat Protein Group
In Meat Protein, the Company's strategy is to drive profitable
growth. Given the unprecedented market dynamics, marked by a
challenging post-pandemic economy, the conflict in Europe, high inflation and significant market
and supply chain disruption, Maple Leaf Foods expects that its Meat
Protein Group will achieve the following:
- Mid-to-high single digit sales growth in 2023, driven by
continued momentum in sustainable meats, leveraging brand
leadership, and growth into the U.S. market.
- Adjusted EBITDA Margin expansion to a 14% - 16% target range
once markets normalize including a pork complex in-line with the
five year average.
Plant Protein Group
- In late 2021, the Company announced that it was re-evaluating
its outlook for the Plant Protein Group and launching a
comprehensive review of the overall plant protein category. This
decision was driven by a pronounced slowdown in growth rates in the
category, particularly in the second half of the year, which fueled
the Company's imperative to identify and thoroughly assess the
causes, near and long-term trends, and overall implications. While
the Company's analysis is ongoing, the results to date confirm that
the very high category growth rates previously predicted by many
industry experts are unlikely to be achieved given current customer
feedback, experience, buy rates and household penetration. Based on
this new information, the Company believes that the category will
continue to grow at more modest, but still attractive rates.
Current estimates suggest that the category will grow at an average
annual rate of 10% to 15%, making it a $6
billion to $10 billion market
by 2030. Accordingly, the Company has pivoted its strategy and
investment thesis for the Plant Protein Group and has set a new
goal to deliver neutral or better Adjusted EBITDA in the latter
half of 2023. Work is ongoing to implement this strategy. The
Company expects at least a 50% improvement in Adjusted EBITDA
losses in the first quarter of 2023 versus the same period last
year, representing another sequential improvement versus the fourth
quarter of 2022.
Capital
- For 2023, the Company estimates total capital expenditures to
be less than $250 million. The lower
estimated capital spend for the year compared to the prior estimate
of $275 million to $325 million is primarily driven by the expected
timing of project execution. Up to $120
million will be maintenance capital with the remainder being
growth capital. The growth capital will mainly consist of an
increase in further processed poultry capacity at the Prepared
Meats facility in Brampton,
Ontario, residual expenditures for the London Poultry
facility, an increase in raised without antibiotics hog barn
capacity and expanded capacity in the snacking kits category.
- The Company expects the London,
Ontario poultry facility to start to deliver approximately
$100 million annually of additional
Adjusted EBITDA once fully ramped up which is expected to be by the
end of 2023. Additionally, the Company expects the Bacon Centre of
Excellence to contribute approximately $30
million annually of additional Adjusted EBITDA once fully
ramped up which is expected to be in the second half of 2023.
The ongoing effects of the post-pandemic economy induced supply
chain disruptions and the war in Ukraine are unpredictable and may impact a
number of factors that drive growth in the business, including:
- Agricultural commodity and foreign exchange markets;
- Inflationary cost pressures;
- Disruptions in the global supply chain;
- Availability of labour; and
- The balance between retail and foodservice demand.
For more information on the impact of COVID-19 on the business
and the associated risks, refer to the section titled Response to
COVID-19, and for more information on the factors that may
influence future performance, see the section titled
Forward-Looking Statements in this news release.
The execution of the Company's financial and operational
priorities are embedded in a commitment to deliver shared value for
the benefit of all stakeholders. The Company's guiding pillars to
be the "Most Sustainable Protein Company on Earth" include Better
Food, Better Care, Better Communities, Better Planet and are core
to how Maple Leaf Foods conducts itself. To that end, the Company's
priorities include:
- Better Food - leading the real food movement and
transitioning key brands to 100% "raised without antibiotics".
- Better Care - further advancement of animal care, after
achieving our transition of all sows under management to open
housing systems in 2021, and advancing plans to convert sow barns
acquired in 2022 by the end of 2023.
- Better Communities - investing a minimum of
approximately 1% of pre-tax profit to advance sustainable food
security.
- Better Planet - continuing to amplify its commitment to
carbon neutrality, while focusing on eliminating waste in any
resources it consumes, including food, energy, water, packaging,
and time.
Non-IFRS Financial Measures
The Company uses the following non-IFRS measures: Adjusted
Operating Earnings, Adjusted Earnings per Share, Adjusted EBITDA,
Adjusted EBITDA Margin, Construction Capital, Net Debt, Free Cash
Flow and Return on Net Assets. Management believes that these
non-IFRS measures provide useful information to investors in
measuring the financial performance of the Company for the reasons
outlined below. These measures do not have a standardized meaning
prescribed by IFRS and therefore they may not be comparable to
similarly titled measures presented by other publicly traded
companies and should not be construed as an alternative to other
financial measures determined in accordance with IFRS.
Adjusted Operating Earnings, Adjusted EBITDA and Adjusted
EBITDA Margin
Adjusted Operating Earnings, Adjusted EBITDA and Adjusted EBITDA
Margin are non-IFRS measures used by Management to evaluate
financial operating results. Adjusted Operating Earnings is defined
as earnings before income taxes adjusted for items that are not
considered representative of ongoing operational activities of the
business and certain items where the economic impact of the
transactions will be reflected in earnings in future periods when
the underlying asset is sold or transferred. Adjusted EBITDA is
defined as Adjusted Operating Earnings plus depreciation and
intangible asset amortization, adjusted for items included in other
expense that are not considered representative of ongoing
operational activities of the business. Adjusted EBITDA Margin is
calculated as Adjusted EBITDA divided by sales.
The tables below provide a reconciliation of earnings (loss)
before income taxes as reported under IFRS in the Consolidated
Financial Statements to Adjusted Operating Earnings and Adjusted
EBITDA for the three and twelve months ended December 31, as indicated below. Management
believes that these non-IFRS measures are useful in assessing the
performance of the Company's ongoing operations and its ability to
generate cash flows to fund its cash requirements, including the
Company's capital investment program.
|
Three months ended
December 31, 2022
|
Three months ended
December 31, 2021
|
|
($
millions)(i) (Unaudited)
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
Total
|
|
Earnings (loss)
before income taxes
|
$
(0.4)
|
(29.4)
|
0.2
|
$
(29.6)
|
$ 67.8
|
(49.9)
|
(10.7)
|
$
7.3
|
|
Interest expense and
other financing costs
|
—
|
—
|
23.0
|
23.0
|
—
|
—
|
6.5
|
6.5
|
|
Impairment of
goodwill
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Other expense
(income)
|
0.5
|
(0.4)
|
5.5
|
5.5
|
3.0
|
0.1
|
4.2
|
7.3
|
|
Restructuring and other
related costs
|
2.1
|
3.6
|
—
|
5.7
|
1.2
|
—
|
—
|
1.2
|
|
Earnings (loss) from
operations
|
$
2.2
|
(26.2)
|
28.7
|
$
4.7
|
$ 72.0
|
(49.8)
|
0.1
|
$ 22.3
|
|
Start-up expenses from
Construction Capital(iii)
|
25.8
|
—
|
—
|
25.8
|
5.8
|
2.0
|
—
|
7.7
|
|
Change in fair value of
biological assets
|
—
|
—
|
(27.0)
|
(27.0)
|
—
|
—
|
(0.3)
|
(0.3)
|
|
Unrealized (gain) loss
on derivative contracts
|
—
|
—
|
(1.7)
|
(1.7)
|
—
|
—
|
0.2
|
0.2
|
|
Adjusted Operating
Earnings
|
$
28.0
|
(26.2)
|
—
|
$
1.8
|
$ 77.8
|
(47.8)
|
—
|
$ 30.0
|
|
Depreciation and
amortization
|
48.6
|
5.4
|
—
|
54.0
|
45.9
|
4.1
|
—
|
49.9
|
|
Items included in other
income (expense)
representative of ongoing
operations(iv)
|
(0.5)
|
0.4
|
(0.5)
|
(0.6)
|
(3.0)
|
(0.1)
|
(0.4)
|
(3.5)
|
|
Adjusted
EBITDA
|
$
76.1
|
(20.4)
|
(0.5)
|
$
55.3
|
$
120.7
|
(43.9)
|
(0.4)
|
$ 76.3
|
|
Adjusted EBITDA
Margin
|
6.6 %
|
(51.0) %
|
n/a
|
4.7 %
|
11.1 %
|
(96.6) %
|
n/a
|
6.8 %
|
|
(i)
|
Totals may not add due to
rounding.
|
(ii)
|
Non-allocated
includes eliminations of inter-segment sales and associated cost of
goods sold, and non-allocated costs which are comprised of income
and expenses not separately identifiable to reportable segments or
are not part of the measures used by the Company when assessing a
segment's operating results.
|
(iii)
|
Start-up expenses are temporary costs as a result of
operating new facilities that are or have been classified as
Construction Capital. These costs can include training, product
testing, yield and labour efficiency variances, duplicative
overheads and other temporary expenses required to ramp-up
production.
|
(iv)
|
2022 primarily
includes legal settlements, gains and losses on investments, gains
and losses on the sale of long-term assets, and other miscellaneous
expenses. 2021 primarily includes legal settlements, gains and
losses on the sale of long-term assets, and other miscellaneous
expenses.
|
|
Twelve months ended
December 31, 2022
|
Twelve months ended
December 31, 2021
|
($
millions)(i)
(Unaudited)
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Earnings (loss)
before income taxes
|
$
123.2
|
(344.6)
|
(77.6)
|
$
(299.0)
|
$
336.1
|
(146.1)
|
(40.3)
|
$
149.7
|
Interest expense and
other financing costs
|
—
|
—
|
56.0
|
56.0
|
—
|
—
|
22.9
|
22.9
|
Impairment of
goodwill
|
—
|
190.9
|
—
|
190.9
|
—
|
—
|
—
|
—
|
Other
expense
|
5.0
|
1.8
|
7.5
|
14.4
|
1.5
|
0.5
|
12.5
|
14.5
|
Restructuring and other
related costs
|
7.5
|
22.6
|
—
|
30.1
|
4.9
|
—
|
—
|
4.9
|
Earnings (loss) from
operations
|
$
135.8
|
(129.3)
|
(14.0)
|
$ (7.6)
|
$
342.5
|
(145.6)
|
(4.9)
|
$
192.0
|
Start-up expenses from
Construction Capital(iii)
|
54.5
|
4.8
|
—
|
59.3
|
9.9
|
3.5
|
—
|
13.4
|
Change in fair value of
biological assets
|
—
|
—
|
15.1
|
15.1
|
—
|
—
|
6.5
|
6.5
|
Unrealized gain on
derivative contracts
|
—
|
—
|
(1.1)
|
(1.1)
|
—
|
—
|
(1.6)
|
(1.6)
|
Adjusted Operating
Earnings
|
$
190.3
|
(124.5)
|
—
|
$
65.7
|
$
352.4
|
(142.1)
|
—
|
$
210.3
|
Depreciation and
amortization
|
193.5
|
18.9
|
—
|
212.4
|
180.2
|
15.4
|
—
|
195.6
|
Items included in other
income (expense)
representative of ongoing
operations(iv)
|
(5.0)
|
0.2
|
(0.5)
|
(5.3)
|
(5.5)
|
(0.5)
|
(0.4)
|
(6.5)
|
Adjusted
EBITDA
|
$
378.7
|
(105.4)
|
(0.5)
|
$
272.9
|
$
527.1
|
(127.2)
|
(0.4)
|
$
399.5
|
Adjusted EBITDA
Margin
|
8.2 %
|
(62.2 %)
|
n/a
|
5.8 %
|
12.1 %
|
(69.1 %)
|
n/a
|
8.8 %
|
(i)
|
Totals may not add due to
rounding.
|
(ii)
|
Non-allocated
includes eliminations of inter-segment sales and associated cost of
goods sold, and non-allocated costs which are comprised of income
and expenses not separately identifiable to reportable segments or
are not part of the measures used by the Company when assessing a
segment's operating results.
|
(iii)
|
Start-up expenses are temporary costs as a result of
operating new facilities that are or have been classified as
Construction Capital. These costs can include training, product
testing, yield and labour efficiency variances, duplicative
overheads and other temporary expenses required to ramp-up
production.
|
(iv)
|
2022 primarily
includes legal settlements, gains and losses on investments, gains
and losses on the sale of long-term assets, and other miscellaneous
expenses. 2021 primarily includes legal settlements, gains and
losses on the sale of long-term assets, and other miscellaneous
expenses.
|
Adjusted Earnings per Share
Adjusted Earnings per Share, a non-IFRS measure, is used by
Management to evaluate financial operating results. It is defined
as basic earnings per share and is adjusted on the same basis as
Adjusted Operating Earnings. The table below provides a
reconciliation of basic earnings per share as reported under
IFRS in the Consolidated Financial Statements to Adjusted Earnings
per Share for the years ended December
31, as indicated below. Management believes this basis is
the most appropriate on which to evaluate financial results as they
are representative of the ongoing operations of the Company.
Adjusted Earnings per Share is calculated as Adjusted Earnings
divided by the weighted average number of shares outstanding during
the year.
($ per
share)
(Unaudited)
|
Three months ended
December 31,
|
Twelve months ended
December 31,
|
2022
|
2021
|
2022
|
2021
|
Basic (loss) earnings
per share
|
|
$
(0.34)
|
|
$
0.02
|
|
$
(2.52)
|
|
$
0.83
|
Impairment of
goodwill
|
|
—
|
|
—
|
|
1.54
|
|
—
|
Restructuring and other
related costs(i)
|
|
0.04
|
|
0.01
|
|
0.20
|
|
0.03
|
Items included in other
expense not considered
representative of ongoing
operations(ii)
|
|
0.03
|
|
0.02
|
|
0.06
|
|
0.06
|
Start-up expenses from
Construction Capital(iii)
|
|
0.16
|
|
0.05
|
|
0.36
|
|
0.08
|
Change in fair value of
biological assets
|
|
(0.16)
|
|
—
|
|
0.09
|
|
0.04
|
Change in unrealized
fair value on derivatives
|
|
(0.01)
|
|
—
|
|
(0.01)
|
|
(0.01)
|
Adjusted Earnings
per Share(iv)
|
|
$
(0.28)
|
|
$
0.09
|
|
$
(0.26)
|
|
$
1.03
|
(i)
|
Includes per share
impact of restructuring and other related costs, net of
tax.
|
(ii)
|
Primarily includes
legal fees, gains or losses on investment property, and transaction
related costs, net of tax.
|
(iii)
|
Start-up expenses are temporary costs as a result of
operating new facilities that are or have been classified as
Construction Capital. These costs can include training, product
testing, yield and labour efficiency variances, duplicative
overheads and other temporary expenses required to ramp-up
production.
|
(iv)
|
Totals may not add
due to rounding.
|
Construction Capital
Construction Capital, a non-IFRS measure, is used by Management
to evaluate the amount of capital resources invested in specific
strategic development projects that are not yet operational. It is
defined as investments and related financing charges in projects
over $50.0 million that are related
to longer-term strategic initiatives, with no returns expected for
at least 12 months from commencement of construction and the asset
is re-categorized from Construction Capital once operational. The
current balance of Construction Capital includes investments to
increase further processed poultry capacity in the Prepared Meats
facility in Brampton, Ontario. The
expansion of the Bacon Centre of Excellence in Winnipeg, Manitoba, was completed in the
fourth quarter of 2021 and recategorized. Investments in capacity
at the Walker Drive facility in Brampton,
Ontario, the plant protein production facility in
Indianapolis, Indiana and the
London, Ontario poultry production
facility were completed in the first and fourth quarters of 2022
respectively, and have been recategorized. The following table is a
summary of Construction Capital activity and debt financing for the
periods indicated below.
($
thousands)
|
|
2022
|
|
2021
|
Property and
equipment and intangibles at January 1
|
|
$
2,554,483
|
|
$
2,062,683
|
Other capital and
intangible assets at January 1(i)
|
|
1,811,164
|
|
1,622,094
|
Construction Capital
at January 1
|
|
$ 743,319
|
|
$ 440,589
|
Additions
|
|
163,665
|
|
494,048
|
Transfers from
Construction Capital
|
|
(897,418)
|
|
(191,318)
|
Construction Capital
at December 31(ii)
|
|
$
9,566
|
|
$ 743,319
|
Other capital and
intangible assets at December 31(i)
|
|
2,654,419
|
|
1,811,164
|
Property and
equipment and Intangibles at December 31
|
|
$
2,663,985
|
|
$
2,554,483
|
|
|
|
|
|
Construction Capital
debt financing(iii)(iv)
|
|
$
9,461
|
|
$ 719,216
|
(i)
|
Other capital and
intangible assets consists of property and equipment and
intangibles that do not meet the definition of Construction
Capital.
|
(ii)
|
As at
December 31, 2022, the net book value of Construction Capital
does not include costs related to intangible assets of nil (2021:
$2.5 million).
|
(iii)
|
Does not include $993.1 million in capital that has
been transferred out but is still in the start-up stage (2021:
$195.3 million).
|
(iv)
|
Assumed to be fully funded by debt to the extent that
the Company has Net Debt outstanding. Construction Capital debt
financing excludes interest paid and
capitalized.
|
Net Debt
The following table reconciles Net Debt to amounts reported
under IFRS in the Company's Consolidated Financial Statements as at
December 31, as indicated below. The Company calculates Net
Debt as cash and cash equivalents, less long-term debt and bank
indebtedness. Management believes this measure is useful in
assessing the amount of financial leverage employed.
|
|
As at December
31,
|
($
thousands)
|
|
2022
|
|
2021
|
Cash and cash
equivalents
|
|
$
91,076
|
|
$
162,031
|
Current portion of
long-term debt
|
|
$
(921)
|
|
$
(5,176)
|
Long-term
debt
|
|
(1,709,493)
|
|
(1,247,073)
|
Total
debt
|
|
$
(1,710,414)
|
|
$
(1,252,249)
|
Net
Debt
|
|
$
(1,619,338)
|
|
$
(1,090,218)
|
Free Cash Flow
Free Cash Flow, a non-IFRS measure, is used by Management to
evaluate cash flow after investing in the maintenance of the
Company's asset base. It is defined as cash provided by operations,
less Maintenance Capital(i) and associated
interest paid and capitalized. During 2022 Management has
re-evaluated the definition of Free Cash flow, moving from
deducting total capital expenditure to deducting only Maintenance
Capital in the calculation as this more accurately represents cash
that is available for capital allocation. The following table
calculates Free Cash Flow for the periods indicated below:
($ thousands)
(Unaudited)
|
Three months ended
December 31,
|
|
Twelve months ended
December 31,
|
2022
|
2021
|
|
2022
|
|
2021
|
Cash provided by
operating activities
|
|
$
42,320
|
|
$
168,290
|
|
|
$
49,318
|
|
$
304,791
|
Maintenance
Capital(i)
|
|
(21,528)
|
|
(23,946)
|
|
|
(69,889)
|
|
(91,172)
|
Interest paid and
capitalized related to
Maintenance Capital
|
|
(88)
|
|
(134)
|
|
|
(323)
|
|
(603)
|
Free Cash
Flow(ii)
|
|
$
20,704
|
|
$
144,210
|
|
|
$
(20,894)
|
|
$
213,016
|
(i)
|
Maintenance Capital
is defined as non-discretionary investment required to maintain the
Company's existing operations and competitive position. Growth
Capital is defined as discretionary investment meant to create
stakeholder value through initiatives that for example, expand
margins, increase capacities or create further competitive
advantage. For the twelve months ended December 31, total capital
spending of $355.7 million (2021: $580.4 million) shown on the
Consolidated Statements of Cash Flows is made up of Maintenance
Capital of $69.9 million (2021: $91.2 million), and Growth Capital
of $285.8 million (2021: $489.2 million). For the three months
ended December 31, total capital spending of $98.0 million (2021:
$121.7 million) is made up of Maintenance Capital of $21.5 million
(2021: $23.9 million), and Growth Capital of $ 76.5 million (2021:
$97.8 million).
|
(ii)
|
Certain comparative
figures have been restated to conform with current year
presentation.
|
Return on Net Assets ("RONA")
RONA is calculated by dividing tax effected earnings from
operations (adjusted for items which are not considered
representative of the underlying operations of the business) by
average monthly net assets. Net assets are defined as total assets
(excluding cash and deferred tax assets) less non-interest bearing
liabilities (excluding deferred tax liabilities). Management
believes that RONA is an appropriate basis upon which to evaluate
long-term financial performance.
Forward-Looking Statements
This document contains, and the Company's oral and written
public communications often contain, "forward-looking information"
within the meaning of applicable securities law. These statements
are based on current expectations, estimates, projections, beliefs,
judgements and assumptions based on information available at the
time the applicable forward-looking statement was made and in light
of the Company's experience combined with its perception of
historical trends. Such statements include, but are not limited to,
statements with respect to objectives and goals, in addition to
statements with respect to beliefs, plans, targets, goals,
objectives, expectations, anticipations, estimates, and intentions.
Forward-looking statements are typically identified by words such
as "anticipate", "continue", "estimate", "expect", "may", "will",
"project", "should", "could", "would", "believe", "plan", "intend",
"design", "target", "undertake", "view", "indicate", "maintain",
"explore", "entail", "schedule", "objective", "strategy", "likely",
"potential", "outlook", "aim", "propose", "goal", and similar
expressions suggesting future events or future performance. These
statements are not guarantees of future performance and involve
assumptions, risks and uncertainties that are difficult to
predict.
By their nature, forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results or events to differ materially from those
anticipated in such forward-looking statements. The Company
believes the expectations reflected in the forward-looking
statements are reasonable, but no assurance can be given that these
expectations will prove to be correct and such forward-looking
statements should not be unduly relied upon.
Specific forward-looking information in this document may
include, but is not limited to, statements with respect to:
- implications of COVID-19 and post-pandemic recovery, including
impact on supply chain, workforce availability and consumption
patterns;
- future performance, including future financial objectives,
goals and targets, category growth analysis, expected capital spend
and expected SG&A expenditures, North American pork market
dynamics, Japan export market
margin outlook, labour markets and inflationary pressures
(including the ability to price for inflation);
- the nature, cause and impact of the cybersecurity incident on
the Company's systems, business and operations, as well as the
ability to mitigate the financial and operational impact of the
cybersecurity incident, the success of remediation and recovery
efforts, the implications of data exfiltration, and ongoing risks
associated with cybersecurity;
- the execution of the Company's business strategy, including the
development and expected timing of business initiatives, brand
expansion and repositioning, plant protein category investment and
performance, market access in China and Japan, capital allocation decisions (including
investment in share repurchases under the NCIB) and investment in
potential growth opportunities and the expected returns associated
therewith;
- the impact of international trade conditions and markets on the
Company's business, including access to markets, implications
associated with the spread of foreign animal disease (such as
African Swine Fever ("ASF")) and other animal diseases such as
Avian Influenza, as well as other social, economic and political
factors that affect trade, including the war in Ukraine;
- competitive conditions and the Company's ability to position
itself competitively in the markets in which it competes;
- capital projects, including planning, construction, estimated
expenditures, schedules, approvals, expected capacity, in-service
dates and anticipated benefits of construction of new facilities
and expansions of existing facilities;
- the Company's dividend policy, including future levels and
sustainability of cash dividends, the tax treatment thereof and
future dividend payment dates;
- the impact of commodity prices and foreign exchange impacts on
the Company's operations and financial performance, including the
use and effectiveness of hedging instruments;
- expected future cash flows and the sufficiency thereof, sources
of capital at attractive rates, future contractual obligations,
future financing options, renewal of credit facilities, compliance
with credit facility covenants, and availability of capital to fund
growth plans, operating obligations and dividends;
- operating risks, including the execution, monitoring and
continuous improvement of the Company's food safety programs,
animal health initiatives, cost reduction initiatives, and service
levels (including service level penalties);
- the implementation, cost and impact of environmental
sustainability initiatives, the ability of the Company to achieve
its sustainability objectives, changing climate and sustainability
laws and regulation, changes in customer and consumer expectations
related to sustainability matters, as well as the anticipated
future cost of remediating environmental liabilities;
- the adoption of new accounting standards and the impact of such
adoption on the financial position of the Company;
- expectations regarding pension plan performance, including
future pension plan assets, liabilities and contributions; and
- developments and implications of actual or potential legal
actions.
Various factors or assumptions are typically applied by the
Company in drawing conclusions or making the forecasts,
projections, predictions or estimations set out in the
forward-looking statements. These factors and assumptions are based
on information currently available to the Company, including
information obtained by the Company from third-party sources and
include but are not limited to the following:
- expectations regarding the ongoing impact and future
implications of COVID-19 and post-pandemic recovery, including
adaptations in operations, supply chain, customer and consumer
behaviour, economic patterns (including but not limited to pork
markets in North America and
internationally), foreign exchange rates and international trade
dynamics;
- the competitive environment, associated market conditions and
market share metrics, category growth or contraction, the expected
behaviour of competitors and customers and trends in consumer
preferences;
- the success of the Company's business strategy, including
execution of the strategy in the Meat Protein Group, the execution
of the Adjusted EBITDA neutral strategy for the Plant Protein Group
and the relationship between pricing, inflation, volume and sales
of the Company's products;
- prevailing commodity prices (especially in pork and feed
markets), interest rates, tax rates and exchange rates;
- the timing and complexity of recovery from the cybersecurity
incident, the risks associated with data exfiltration, the
availability of insurance, the effectiveness of remediation and
prevention activities, third party activities, ongoing impacts,
customer, consumer and supplier responses and regulatory
considerations;
- the economic condition of and the sociopolitical dynamics
between Canada, the U.S.,
Japan and China, and the ability of the Company to
access markets and source ingredients and other inputs in light of
global sociopolitical disruption, and the ongoing impact of the war
in Ukraine on international
relations, trade and markets;
- the spread of foreign animal disease (including ASF and Avian
Influenza), preparedness strategies to manage such spread, and
implications for all protein markets;
- the availability of capital to fund future capital requirements
associated with existing operations, assets and projects;
- expectations regarding participation in and funding of the
Company's pension plans;
- the availability of insurance coverage to manage certain
liability exposures;
- the extent of future liabilities and recoveries related to
legal claims;
- prevailing regulatory, tax and environmental laws; and
- future operating costs and performance, including the Company's
ability to achieve operating efficiencies and maintain high sales
volumes, high turnover of inventories and high turnover of accounts
receivable.
Readers are cautioned that these assumptions may prove to be
incorrect in whole or in part. The Company's actual results may
differ materially from those anticipated in any forward-looking
statements.
Factors that could cause actual results or outcomes to differ
materially from the results expressed, implied, or projected in the
forward-looking statements contained in this document include,
among other things, risks associated with the following:
- implications of COVID-19 and post-pandemic recovery on the
operations and financial performance of the Company, as well the
ongoing implications for macro socio-economic trends;
- macro economic trends, including inflation, recessionary
indicators, labour availability and labour market dynamics and
international trade trends;
- competition, market conditions, and the activities of
competitors and customers, including the expansion or contraction
of key categories. pork market dynamics and Japan export margins;
- cybersecurity and maintenance and operation of the Company's
information systems, processes and data, recovery, restoration and
long term impacts of the cybersecurity event, the risk of future
cybersecurity events, actions of third parties, risks of data
exfiltration, effectiveness of business continuity planning and
execution, and availability of insurance;
- the health status of livestock, including the impact of
potential pandemics;
- international trade and access to markets and supplies, as well
as social, political and economic dynamics, including the war in
Ukraine;
- operating performance, including manufacturing operating
levels, fill rates and penalties;
- availability of and access to capital, and compliance with
credit facility covenants;
- decision respecting the return of capital to shareholders;
- the execution of capital projects, including cost, schedule and
regulatory variables, all of which impact expected returns on
investment;
- food safety, consumer liability and product recalls;
- climate change, climate regulation and the Company's
sustainability performance;
- strategic risk management, including execution of the Adjusted
EBITDA neutral strategy in the plant protein segment;
- acquisitions and divestitures;
- fluctuations in the debt and equity markets;
- fluctuations in interest rates and currency exchange
rates;
- pension assets and liabilities;
- cyclical nature of the cost and supply of hogs and the
competitive nature of the pork market generally;
- the effectiveness of commodity and interest rate hedging
strategies;
- impact of changes in the market value of the biological assets
and hedging instruments;
- the supply management system for poultry in Canada;
- availability of plant protein ingredients;
- intellectual property, including product innovation, product
development, brand strategy and trademark protection;
- consolidation of operations and focus on protein;
- the use of contract manufacturers;
- reputation;
- weather;
- compliance with government regulation and adapting to changes
in laws;
- actual and threatened legal claims;
- consumer trends and changes in consumer tastes and buying
patterns;
- environmental regulation and potential environmental
liabilities;
- consolidation in the retail environment;
- employment matters, including complying with employment laws
across multiple jurisdictions, the potential for work stoppages due
to non-renewal of collective agreements, recruiting and retaining
qualified personnel, reliance on key personnel and succession
planning;
- pricing of products;
- managing the Company's supply chain;
- changes in International Financial Reporting Standards and
other accounting standards that the Company is required to adhere
to for regulatory purposes; and
- other factors as set out under the heading "Risk Factors" in
the Company's Management Discussion and Analysis for the year ended
December 31, 2022.
The Company cautions readers that the foregoing list of factors
is not exhaustive.
Readers are further cautioned that some of the forward-looking
information, such as statements concerning future capital
expenditures, Adjusted EBITDA Margin growth in the Meat Protein
Group, and Adjusted EBITDA target in the Plant Protein Group
(including the timing, pace and impact of restructuring
activities), may be considered to be financial outlooks for
purposes of applicable securities legislation. These financial
outlooks are presented to evaluate potential future earnings and
anticipated future uses of cash flows and may not be appropriate
for other purposes. Readers should not assume these financial
outlooks will be achieved.
More information about risk factors can be found under the
heading "Risk Factors" in the Company's Annual Management's
Discussion and Analysis for the year ended December 31, 2022, that is available on SEDAR at
www.sedar.com. The reader should review such section in detail.
Additional information concerning the Company, including the
Company's Annual Information Form, is available on SEDAR at
www.sedar.com.
All forward-looking statements included herein speak only as of
the date hereof. Unless required by law, the Company does not
undertake any obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise. All forward-looking statements
contained herein are expressly qualified by this cautionary
statement.
About Maple Leaf Foods Inc.
Maple Leaf Foods is a carbon neutral company with a vision
to be the most sustainable protein company on earth, responsibly
producing food products under leading brands including Maple Leaf®,
Maple Leaf Prime®, Maple Leaf Natural Selections®, Schneiders®,
Schneiders® Country Naturals®, Mina®, Greenfield Natural Meat Co.®,
Lightlife® and Field Roast™. The Company employs approximately
14,000 people and does business primarily in Canada, the U.S. and Asia. The Company is headquartered in
Mississauga, Ontario and its
shares trade on the Toronto Stock Exchange (MFI).
Consolidated Balance Sheets
(In thousands of
Canadian dollars)
(Audited)
|
As at December
31,
2022
|
As at December
31,
2021
|
ASSETS
|
|
|
|
|
Cash and cash
equivalents
|
|
$
91,076
|
|
$
162,031
|
Accounts
receivable
|
|
167,611
|
|
167,082
|
Notes
receivable
|
|
48,556
|
|
33,294
|
Inventories
|
|
485,979
|
|
409,677
|
Biological
assets
|
|
144,169
|
|
138,209
|
Income and other taxes
recoverable
|
|
57,497
|
|
1,830
|
Prepaid expenses and
other assets
|
|
50,266
|
|
24,988
|
Assets held for
sale
|
|
604
|
|
—
|
Total current
assets
|
|
$
1,045,758
|
|
$
937,111
|
Property and
equipment
|
|
2,303,424
|
|
2,189,165
|
Right-of-use
assets
|
|
159,199
|
|
161,662
|
Investments
|
|
23,712
|
|
22,326
|
Employee
benefits
|
|
12,531
|
|
—
|
Other long-term
assets
|
|
14,357
|
|
11,644
|
Deferred tax
asset
|
|
42,541
|
|
39,907
|
Goodwill
|
|
477,353
|
|
658,673
|
Intangible
assets
|
|
360,561
|
|
365,318
|
Total long-term
assets
|
|
$
3,393,678
|
|
$ 3,448,695
|
Total
assets
|
|
$
4,439,436
|
|
$ 4,385,806
|
LIABILITIES AND
EQUITY
|
|
|
|
|
Accounts payable and
accruals
|
|
$
485,114
|
|
$
526,189
|
Current portion of
provisions
|
|
42,589
|
|
842
|
Current portion of
long-term debt
|
|
921
|
|
5,176
|
Current portion of
lease obligations
|
|
38,321
|
|
31,375
|
Income taxes
payable
|
|
2,311
|
|
23,853
|
Other current
liabilities
|
|
64,684
|
|
81,265
|
Total current
liabilities
|
|
$
633,940
|
|
$
668,700
|
Long-term
debt
|
|
1,709,493
|
|
1,247,073
|
Lease
obligations
|
|
144,569
|
|
144,391
|
Employee
benefits
|
|
64,280
|
|
97,629
|
Provisions
|
|
3,799
|
|
44,650
|
Other long-term
liabilities
|
|
1,841
|
|
1,057
|
Deferred tax
liability
|
|
220,926
|
|
146,380
|
Total long-term
liabilities
|
|
$
2,144,908
|
|
$ 1,681,180
|
Total
liabilities
|
|
$
2,778,848
|
|
$ 2,349,880
|
Shareholders'
equity
|
|
|
|
|
Share
capital
|
|
$
850,086
|
|
$
847,016
|
Retained
earnings
|
|
809,616
|
|
1,212,244
|
Contributed
surplus
|
|
—
|
|
5,371
|
Accumulated other
comprehensive income (loss)
|
|
26,802
|
|
(2,459)
|
Treasury
stock
|
|
(25,916)
|
|
(26,246)
|
Total shareholders'
equity
|
|
$
1,660,588
|
|
$ 2,035,926
|
Total liabilities
and equity
|
|
$
4,439,436
|
|
$ 4,385,806
|
Consolidated Statements of Net Earnings
|
Three months ended
December 31,
|
Twelve months ended
December 31,
|
(In thousands of
Canadian dollars, except share amounts)
|
|
2022
|
|
2021
|
|
2022
|
|
2021
|
|
|
(Unaudited)
|
|
(Unaudited)
|
|
(Audited)
|
|
(Audited)
|
Sales
|
|
$
1,185,522
|
|
$
1,120,495
|
|
$
4,739,063
|
|
$
4,521,082
|
Cost of goods
sold
|
|
1,084,947
|
|
978,188
|
|
4,314,925
|
|
3,862,007
|
Gross profit
|
|
$
100,575
|
|
$
142,307
|
|
$
424,138
|
|
$
659,075
|
Selling, general and
administrative expenses
|
|
95,850
|
|
120,000
|
|
431,715
|
|
467,067
|
(Loss) earnings before
the following:
|
|
$
4,725
|
|
$
22,307
|
|
$
(7,577)
|
|
$
192,008
|
Restructuring and other
related costs
|
|
5,694
|
|
1,212
|
|
30,083
|
|
4,910
|
Other expense
(income)
|
|
5,547
|
|
7,328
|
|
14,356
|
|
14,522
|
Impairment of
goodwill
|
|
—
|
|
—
|
|
190,911
|
|
—
|
(Loss) earnings before
interest and income taxes
|
|
$
(6,516)
|
|
$
13,767
|
|
$ (242,927)
|
|
$
172,576
|
Interest expense and
other financing costs
|
|
23,045
|
|
6,508
|
|
56,041
|
|
22,870
|
(Loss) earnings before
income taxes
|
|
$
(29,561)
|
|
$
7,259
|
|
$ (298,968)
|
|
$
149,706
|
Income tax
expense
|
|
11,931
|
|
5,381
|
|
12,925
|
|
46,883
|
Net (loss)
earnings
|
|
$
(41,492)
|
|
$
1,878
|
|
$ (311,893)
|
|
$
102,823
|
(Loss) earnings per
share attributable to common
shareholders:
|
|
|
|
|
|
|
|
|
Basic (loss) earnings
per share
|
|
$
(0.34)
|
|
$
0.02
|
|
$
(2.52)
|
|
$
0.83
|
Diluted (loss)
earnings per share
|
|
$
(0.34)
|
|
$
0.01
|
|
$
(2.52)
|
|
$
0.82
|
Weighted average number
of shares (millions):
|
|
|
|
|
|
|
|
|
Basic
|
|
122.5
|
|
123.9
|
|
123.6
|
|
123.5
|
Diluted
|
|
122.5
|
|
125.3
|
|
123.6
|
|
124.7
|
Consolidated Statements of Other Comprehensive Income
(Loss)
(In thousands of
Canadian dollars)
|
Three months ended
December 31,
|
Twelve months ended
December 31,
|
|
2022
|
|
2021
|
|
2022
|
|
2021
|
|
|
(Unaudited)
|
|
(Unaudited)
|
|
(Audited)
|
|
(Audited)
|
Net (loss)
earnings
|
|
$
(41,492)
|
|
$
1,878
|
|
$
(311,893)
|
|
$
102,823
|
Other comprehensive
income (loss)
|
|
|
|
|
|
|
|
|
Actuarial (losses)
gains that will not be reclassified to
profit or loss (Net of tax of $0.0 million and
$14.6
million;
2021: $1.2 million and $24.6
million)
|
|
$
17,910
|
|
$
(2,215)
|
|
$
40,095
|
|
$
73,502
|
Items that are or may
be reclassified subsequently to profit
or
loss:
|
|
|
|
|
|
|
|
|
Change in fair value
of investments (Net of tax of $0.0
million and $0.0 million; 2021: $0.0 million and
$1.0
million)
|
|
$
—
|
|
$
—
|
|
$
—
|
|
$
2,945
|
Change in accumulated
foreign currency translation
adjustment (Net of tax of $0.0 million and $0.0
million; 2021: $0.0 million and $0.0
million)
|
|
(6,096)
|
|
702
|
|
28,972
|
|
(3,181)
|
Change in foreign
exchange on long-term debt
designated as a net investment hedge (Net of tax
of
$0.0 million and $3.8 million; 2021: $0.1 million
and
$0.5 million)
|
|
6,313
|
|
390
|
|
(20,037)
|
|
2,216
|
Change in cash flow
hedges (Net of tax of $0.0 million
and $6.3 million; 2021: $1.5 million and $3.2
million)
|
|
3,896
|
|
4,338
|
|
20,326
|
|
8,975
|
Total items that are or
may be reclassified subsequently
to profit or loss
|
|
$
4,113
|
|
$
5,430
|
|
$
29,261
|
|
$
10,955
|
Total other
comprehensive income
|
|
$
22,023
|
|
$
3,215
|
|
$
69,356
|
|
$
84,457
|
Comprehensive (loss)
income
|
|
$
(19,469)
|
|
$
5,093
|
|
$ (242,537)
|
|
$
187,280
|
Consolidated Statements of Changes in Total Equity
|
|
|
|
Accumulated other
comprehensive
income (loss)(i)
|
|
|
(In thousands of Canadian dollars)
(Unaudited)
|
Share
capital
|
Retained
earnings
|
Contributed
surplus
|
Foreign
currency
translation
adjustment
|
Unrealized
gains and
losses on
cash flow
hedges
|
Unrealized
gains on fair
value of
investments
|
Treasury
stock
|
Total
equity
|
Balance at December
31, 2021
|
$
847,016
|
1,212,244
|
5,371
|
2,037
|
(7,441)
|
2,945
|
(26,246)
|
$
2,035,926
|
Net loss
|
—
|
(311,893)
|
—
|
—
|
—
|
—
|
—
|
(311,893)
|
Other comprehensive
income (loss)(ii)
|
—
|
40,095
|
—
|
8,935
|
20,326
|
—
|
—
|
69,356
|
Dividends declared
($0.80 per
share)
|
—
|
(99,084)
|
—
|
—
|
—
|
—
|
—
|
(99,084)
|
Share-based
compensation
expense
|
—
|
—
|
20,121
|
—
|
—
|
—
|
—
|
20,121
|
Modification of stock
compensation
plan
|
—
|
—
|
(3,595)
|
—
|
—
|
—
|
—
|
(3,595)
|
Deferred taxes on
share-based
compensation
|
—
|
—
|
(1,350)
|
—
|
—
|
—
|
—
|
(1,350)
|
Exercise of stock
options
|
7,433
|
—
|
(1,289)
|
—
|
—
|
—
|
—
|
6,144
|
Shares
re-purchased
|
(17,400)
|
(10,758)
|
(30,719)
|
—
|
—
|
—
|
—
|
(58,877)
|
Shares purchased by
RSU trust
|
—
|
—
|
—
|
—
|
—
|
—
|
(7,500)
|
(7,500)
|
Settlement of
share-based
compensation
|
—
|
—
|
(15,560)
|
—
|
—
|
—
|
7,830
|
(7,730)
|
Change in obligation
for
repurchase of shares
|
13,037
|
(20,988)
|
27,021
|
—
|
—
|
—
|
—
|
19,070
|
Balance at December
31, 2022
|
$
850,086
|
809,616
|
—
|
10,972
|
12,885
|
2,945
|
(25,916)
|
$
1,660,588
|
|
|
|
|
|
|
Accumulated other
comprehensive
income (loss)(i)
|
|
|
(In thousands of Canadian dollars)
(Unaudited)
|
Share
capital
|
Retained
earnings
|
Contributed
surplus
|
Foreign
currency
translation
adjustment
|
Unrealized
gains and
losses on cash
flow hedges
|
Unrealized
gains on fair
value of
investments
|
Treasury
stock
|
Total
equity
|
Balance at December 31,
2020
|
$ 838,969
|
1,124,973
|
5,866
|
3,002
|
(16,416)
|
—
|
(23,930)
|
$ 1,932,464
|
Net
earnings
|
—
|
102,823
|
—
|
—
|
—
|
—
|
—
|
102,823
|
Other comprehensive
income (loss)(ii)
|
—
|
73,502
|
—
|
(965)
|
8,975
|
2,945
|
—
|
84,457
|
Dividends declared
($0.72 per
share)
|
—
|
(89,054)
|
—
|
—
|
—
|
—
|
—
|
(89,054)
|
Share-based
compensation
expense
|
—
|
—
|
21,960
|
—
|
—
|
—
|
—
|
21,960
|
Deferred taxes on
share-based
compensation
|
—
|
—
|
975
|
—
|
—
|
—
|
—
|
975
|
Exercise of stock
options
|
16,414
|
—
|
(2,882)
|
—
|
—
|
—
|
—
|
13,532
|
Settlement of
share-based
compensation
|
—
|
—
|
(9,679)
|
—
|
—
|
—
|
5,192
|
(4,487)
|
Shares purchased by
RSU trust
|
—
|
—
|
—
|
—
|
—
|
—
|
(7,508)
|
(7,508)
|
Change in obligation
for
repurchase of shares
|
(8,367)
|
—
|
(10,869)
|
—
|
—
|
—
|
—
|
(19,236)
|
Balance at December 31,
2021
|
$ 847,016
|
1,212,244
|
5,371
|
2,037
|
(7,441)
|
2,945
|
(26,246)
|
$ 2,035,926
|
(i)
|
Items that are or may be subsequently reclassified to
profit or loss.
|
(ii)
|
Included in other comprehensive income (loss) is the
change in actuarial gains and losses that will not be reclassified
to profit or loss and has been reclassified to retained
earnings.
|
Consolidated Statements of Cash Flows
(In thousands of
Canadian dollars)
|
Three months ended
December 31,
|
Twelve months ended
December 31,
|
2022
|
2021
|
2022
|
2021
|
CASH PROVIDED BY (USED
IN):
|
(Unaudited)
|
(Unaudited)
|
(Audited)
|
(Audited)
|
Operating
activities
|
|
|
|
|
|
|
|
|
Net
earnings
|
|
$
(41,492)
|
|
$
1,878
|
|
$
(311,893)
|
|
$ 102,823
|
Add (deduct) items not
affecting cash:
|
|
|
|
|
|
|
|
|
Change in fair value
of biological assets
|
|
(26,996)
|
|
(304)
|
|
15,108
|
|
6,474
|
Depreciation and
amortization
|
|
61,905
|
|
52,654
|
|
233,937
|
|
200,855
|
Share-based
compensation
|
|
2,902
|
|
4,222
|
|
19,387
|
|
21,960
|
Deferred income
taxes
|
|
50,791
|
|
369
|
|
57,406
|
|
(17,325)
|
Income tax
current
|
|
(38,860)
|
|
5,012
|
|
(44,481)
|
|
64,208
|
Interest expense and
other financing costs
|
|
23,045
|
|
6,508
|
|
56,041
|
|
22,870
|
Loss on sale of
long-term assets
|
|
280
|
|
1,900
|
|
1,966
|
|
3,819
|
Impairments
|
|
3,353
|
|
308
|
|
212,363
|
|
744
|
Change in fair value
of non-designated
derivatives
|
|
14,451
|
|
12,586
|
|
(4,956)
|
|
10,211
|
Change in net pension
obligation
|
|
1,826
|
|
3,151
|
|
8,764
|
|
6,745
|
Net income taxes
paid
|
|
(304)
|
|
(12,347)
|
|
(30,162)
|
|
(69,595)
|
Interest paid, net of
capitalized interest
|
|
(20,483)
|
|
(5,322)
|
|
(54,897)
|
|
(22,088)
|
Change in provision
for restructuring and other
related costs
|
|
(653)
|
|
218
|
|
995
|
|
(6)
|
Change in derivatives
margin
|
|
4,710
|
|
5,446
|
|
2,012
|
|
9,938
|
Other
|
|
6,027
|
|
8,045
|
|
(4,334)
|
|
2,057
|
Change in non-cash
operating working capital
|
|
1,818
|
|
83,966
|
|
(107,938)
|
|
(38,899)
|
Cash provided by
operating activities
|
|
$
42,320
|
|
$ 168,290
|
|
$
49,318
|
|
$ 304,791
|
Investing
activities
|
|
|
|
|
|
|
|
|
Additions to long-term
assets
|
|
$
(97,950)
|
|
$
(121,763)
|
|
$
(355,734)
|
|
$
(580,349)
|
Acquisition of
business
|
|
—
|
|
—
|
|
—
|
|
(41,928)
|
Interest paid and
capitalized
|
|
(5,578)
|
|
(5,819)
|
|
(22,217)
|
|
(20,344)
|
Proceeds from sale of
long-term assets
|
|
484
|
|
731
|
|
607
|
|
1,499
|
Purchase of
investments
|
|
(600)
|
|
—
|
|
(600)
|
|
(3,184)
|
Proceeds from legal
settlement
|
|
929
|
|
—
|
|
929
|
|
20,822
|
Cash used in investing
activities
|
|
$
(102,715)
|
|
$
(126,851)
|
|
$
(377,015)
|
|
$
(623,484)
|
Financing
activities
|
|
|
|
|
|
|
|
|
Dividends
paid
|
|
$
(24,551)
|
|
$ (22,394)
|
|
$
(99,084)
|
|
$ (89,054)
|
Net increase in
long-term debt
|
|
106,571
|
|
81,242
|
|
447,045
|
|
500,297
|
Payment of lease
obligation
|
|
(6,943)
|
|
(9,037)
|
|
(33,892)
|
|
(36,843)
|
Receipt of lease
inducement
|
|
1
|
|
—
|
|
6,848
|
|
—
|
Exercise of stock
options
|
|
1,545
|
|
4,821
|
|
6,144
|
|
13,532
|
Repurchase of
shares
|
|
(31,313)
|
|
—
|
|
(58,877)
|
|
—
|
Payment of financing
fees
|
|
(38)
|
|
—
|
|
(3,942)
|
|
(528)
|
Purchase of treasury
stock
|
|
—
|
|
(7,508)
|
|
(7,500)
|
|
(7,508)
|
Cash provided by
financing activities
|
|
$
45,272
|
|
$
47,124
|
|
$
256,742
|
|
$ 379,896
|
(Decrease) increase
in cash and cash equivalents
|
|
(15,123)
|
|
88,563
|
|
(70,955)
|
|
61,203
|
Cash and cash
equivalents, beginning of period
|
|
106,199
|
|
73,468
|
|
162,031
|
|
100,828
|
Cash and cash
equivalents, end of period
|
|
$
91,076
|
|
$ 162,031
|
|
$
91,076
|
|
$ 162,031
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/maple-leaf-foods-reports-fourth-quarter-and-full-year-2022-financial-results-301766424.html
SOURCE Maple Leaf Foods Inc.